PRVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Privia Health Group Inc (PRVA) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company's financial performance shows solid growth, the lack of strong technical signals, mixed analyst ratings, and recent insider selling suggest waiting for a better entry point.
The MACD is positive and contracting, indicating mild bullish momentum. RSI is neutral at 56.473, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 23.361 with resistance at 24.25 and support at 22.471. Overall, the technical indicators suggest a neutral trend.
Hedge funds are significantly increasing their positions, with a 431.38% increase in buying activity over the last quarter. The company reported strong financial growth in Q4 2025, with revenue up 17.42% YoY and net income up 108.02% YoY.
Insiders are selling heavily, with a 234.74% increase in selling activity over the last month. Analyst price targets have been revised downward by some firms, and the stock is projected to decline slightly in the short term based on candlestick pattern analysis.
In Q4 2025, revenue increased by 17.42% YoY to $541.17M, net income grew by 108.02% YoY to $9.15M, and EPS rose by 133.33% YoY to $0.07. However, gross margin dropped by 13.29% YoY to 8.68%, indicating potential cost pressures.
Analyst ratings are mixed. While some firms like JPMorgan and Jefferies maintain Buy ratings with price targets as high as $35, others like Evercore ISI and Citi have lowered their price targets. The current price of $23.5 is below most price targets, but the mixed sentiment suggests caution.
